Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL10698252 | 0.88 | DNMT1 (0.33) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL3421294 | 0.87 | MAPT (0.36) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL887253 | 0.83 | MAPT (0.39) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL323176 | 0.83 | MAPT (0.39) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL503952 | 0.81 | TP53 (0.38) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL242425 | 0.80 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL11350903 | 0.80 | HTT (0.42) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL108508 | 0.80 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL5800741 | 0.80 | DNMT1 (0.41) | DNMT1TP53MAPTSTAT3HTT | |
| Triaziquone SCHEMBL3903404 | 0.80 | DNMT1 (0.32) | DNMT1TP53MAPTSTAT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806402-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210147582-A1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-05-20 | — | — | US | disclosed |
| US-20210093727-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| US-10851184-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10800861-B2 | Alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10780177-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10323103-B2 | Alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190070303-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-07 | — | — | US | disclosed |
| US-20180346609-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-12-06 | — | — | US | disclosed |
| US-9200088-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150284479-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-10-08 | — | — | US | disclosed |
| US-20150045311-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-02-12 | — | — | US | disclosed |
| US-20130184357-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8410077-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8383606-B2 | — | — | 2013-02-26 | — | — | US | disclosed |
| US-20100093663-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7635773-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090270348-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-10-29 | — | — | US | disclosed |
| WO-2009018069-A2 | MIXTURES OF CYCLODEXTRIN DERIVATIVES | CYDEX PHARMACEUTICALS, INC (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284479-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | AGL, AGPS, MGAM | DNMT1 996/4885TP53 3820/4885MAPT 3069/4885 |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | DNMT1 1914/4885TP53 2173/4885MAPT 2876/4885 |
| US-10323103-B2 | Alkylated cyclodextrin compositions and processes for preparing and using the same | AGL, AGPS, MGAM | DNMT1 996/4885TP53 3820/4885MAPT 3069/4885 |
| US-20090270348-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | SI, SULT1E1, SAE1 | DNMT1 1447/4885TP53 1262/4885MAPT 1472/4885 |
| US-20210147582-A1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | AGPS, DDOST, ALG1 | DNMT1 1914/4885TP53 2173/4885MAPT 2876/4885 |
| US-20100093663-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | SI, SULT1E1, SAE1 | DNMT1 1257/4885TP53 1509/4885MAPT 1744/4885 |
| US-20150045311-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | AGL, AGPS, MGAM | DNMT1 996/4885TP53 3820/4885MAPT 3069/4885 |
| US-10800861-B2 | Alkylated cyclodextrin compositions and processes for preparing and using the same | AGL, AGPS, MGAM | DNMT1 996/4885TP53 3820/4885MAPT 3069/4885 |
| US-20180346609-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | AGL, AGPS, MGAM | DNMT1 996/4885TP53 3820/4885MAPT 3069/4885 |
| US-20190070303-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | SI, SULT1E1, SAE1 | DNMT1 1257/4885TP53 1509/4885MAPT 1744/4885 |
| US-20210093727-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | SI, SULT1E1, SAE1 | DNMT1 1257/4885TP53 1509/4885MAPT 1744/4885 |
| US-10780177-B2 | Sulfoalkyl ether cyclodextrin compositions | SI, SULT1E1, SAE1 | DNMT1 1257/4885TP53 1509/4885MAPT 1744/4885 |
| US-10851184-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | DNMT1 1914/4885TP53 2173/4885MAPT 2876/4885 |
| US-11806402-B2 | Sulfoalkyl ether cyclodextrin compositions | SI, SULT1E1, SAE1 | DNMT1 1257/4885TP53 1509/4885MAPT 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.